ReviewReproductive biology and endocrinology : RB&E2013
Optimal usage of the GnRH antagonists: a review of the literature.
Review in Reproductive biology and endocrinology : RB&E, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Conventional GnRH antagonist protocols versus long GnRH agonist protocol in IVF/ICSI cycles of polycystic ovary syndrome women: a systematic review and meta-analysis.Scientific reports · 2022Pooled it
- Relative Bioavailability of Single-Dose Oral Administration of Two SHR7280 Formulations (Dry Suspension and Tablets) in Healthy Chinese Volunteers.Clinical drug investigation · 2025Trial
- Evaluation of GnRH antagonist pretreatment before ovarian stimulation in a GnRH antagonist protocol in normal ovulatory women undergoing IVF/ICSI: a randomized controlled trial.Reproductive biology and endocrinology : RB&E · 2021Trial
- A randomized controlled trial of gonadotropin-releasing hormone agonist versus gonadotropin-releasing hormone antagonist in Iranian infertile couples: oocyte gene expression.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2014Trial
- Systemic pathways linking subcutaneous therapies to gastrointestinal adverse effects: A Narrative review of mechanisms and mitigation strategies.Indian journal of pharmacology · 2026Review
- Premenstrual Syndrome and Nutritional Factors: A Narrative Review of Current Evidence and Clinical Implications.Journal of clinical medicine · 2026Review
- Medium-sized follicle proportion on the trigger day may be associated with higher live birth rate in fresh embryo transfer cycles among low-prognosis patients: a retrospective cohort study.Frontiers in endocrinology · 2026Article
- Does the Timing of Antagonist Treatment Influence Cycle Outcomes in Unexpected Low Responders of POSEIDON Class 1 and 2?Journal of clinical medicine · 2025Article
- Serum luteinizing hormone trajectories during ovarian stimulation and their outcomes of IVF/ICSI: a retrospective cohort study.Frontiers in endocrinology · 2025Article
- Development and validation of a prediction model for suboptimal ovarian response in polycystic ovary syndrome (PCOS) patients undergoing GnRH-antagonist protocol in IVF/ICSI cycles.Journal of ovarian research · 2024Article
- FSH/LH co-stimulation in Advanced Maternal Age (AMA) and hypo-responder patients - Arabian gulf delphi consensus group.Frontiers in endocrinology · 2024Article
- Premenstrual syndrome: new insights into etiology and review of treatment methods.Frontiers in psychiatry · 2024Review
- Article
- Live birth rates following individualized dosing algorithm of follitropin delta in a long GnRH agonist protocol.Reproductive biology and endocrinology : RB&E · 2023Article
- Effect of the ratios of estradiol increase on the outcome of in vitro fertilization-embryo transfer with antagonist regimens: a single center retrospective cohort study.BMC pregnancy and childbirth · 2023Article
- Effect of Flexible Half-Dose Gonadotropin-Releasing Hormone Antagonist Protocol on in vitro Fertilization Outcome in Predicted Normal Responder: A Study Protocol for a Multicentered, Randomized, Non-Inferiority, Parallel Controlled Trial.Drug design, development and therapy · 2023Article
- Accumulated Vitrified Embryos Could Be a Method for Increasing Pregnancy Rates in Patients with Poor Ovarian Response.Journal of clinical medicine · 2022Article
- Analysis of relative factors and prediction model for optimal ovarian response with gonadotropin-releasing hormone antagonist protocol.Frontiers in endocrinology · 2022Article
- Effects of half-dose and full-dose GnRH antagonists on IVF-ET outcomes: a retrospective study.BMC pregnancy and childbirth · 2021Article
- Cumulative live birth rates between GnRH-agonist long and GnRH-antagonist protocol in one ART cycle when all embryos transferred: real-word data of 18,853 women from China.Reproductive biology and endocrinology : RB&E · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gonadotropin-releasing hormone (GnRH) antagonists, which became commercially available from 1999, have been used for the prevention of premature luteinizing hormone (LH) surges in controlled ovarian stimulation for in vitro fertilization or intracytoplasmic sperm injection. This review focuses on the recent literature on the use of GnRH antagonists and provides guidelines for optimal use in light of increasing evidence showing that GnRH antagonists are safe and effective, allowing flexibility of treatment in a wide range of patient populations. This includes patients undergoing first-line controlled ovarian stimulation, poor responders, and women diagnosed with polycystic ovary syndrome. The GnRH antagonist offers a viable alternative to the long agonists, providing a shorter duration of treatment with fewer injections and with no adverse effects on assisted reproductive technology outcome. This results in a significantly lower amount of gonadotropins required, which is likely to lead to improved patient compliance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.